GB201209344D0 - Omega-6 enriched pufa phospholipids - Google Patents
Omega-6 enriched pufa phospholipidsInfo
- Publication number
- GB201209344D0 GB201209344D0 GBGB1209344.9A GB201209344A GB201209344D0 GB 201209344 D0 GB201209344 D0 GB 201209344D0 GB 201209344 A GB201209344 A GB 201209344A GB 201209344 D0 GB201209344 D0 GB 201209344D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- phospholipids
- omega
- dgla
- pufa
- enriched
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Abstract
Pharmaceutical formulations comprise dihomo gamma linolenic acid (DGLA) or any appropriate metabolite or derivative e.g. 15-hydroxy-DGLA and krill oil (KO). They may be used for the treatment of a wide range of diseases and disorders. They may also be taken as a general nutritional supplement.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1209344.9A GB2504061A (en) | 2012-05-25 | 2012-05-25 | Omega-6 Enriched PUFA Phospholipids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1209344.9A GB2504061A (en) | 2012-05-25 | 2012-05-25 | Omega-6 Enriched PUFA Phospholipids |
Publications (2)
Publication Number | Publication Date |
---|---|
GB201209344D0 true GB201209344D0 (en) | 2012-07-11 |
GB2504061A GB2504061A (en) | 2014-01-22 |
Family
ID=46545984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB1209344.9A Withdrawn GB2504061A (en) | 2012-05-25 | 2012-05-25 | Omega-6 Enriched PUFA Phospholipids |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2504061A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2714323C2 (en) * | 2014-06-04 | 2020-02-14 | ДиЭс БАЙОФАРМА ЛИМИТЕД | Pharmaceutical compositions containing dgla, and use thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666447B2 (en) * | 2004-10-08 | 2010-02-23 | Pharmanutrients | Compositions including Krill extracts and conjugated linoleic acid and methods of using same |
JP6067558B2 (en) * | 2011-06-29 | 2017-01-25 | 日本水産株式会社 | How to reduce fear memory |
-
2012
- 2012-05-25 GB GB1209344.9A patent/GB2504061A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
GB2504061A (en) | 2014-01-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016004487A (en) | Enteric soft capsules comprising polyunsaturated fatty acids. | |
HK1247822A1 (en) | Formulations for oral administration of active agents | |
MY165048A (en) | Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form | |
SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
PH12017502181A1 (en) | Nutritional compositions containing an elevated level of inositol and uses thereof | |
PH12018500090A1 (en) | Nutritional compositions and methods for promoting cognitive development | |
EP3565539A4 (en) | Medicinal compounds and nutritional supplements | |
HK1252651A1 (en) | Nutritional compositions containing phosphatidylethanolamine, sphingomyelin and docosahexaenoic acid | |
PH12018500035A1 (en) | Nutritional compositions and methods for promoting cognitive development | |
EP3416501A4 (en) | Nutritional support for animals via administration of an algal derived supplement | |
NZ631833A (en) | Emulsion formulations | |
TW201613632A (en) | Brain function improving agent, and prophylactic or therapeutic agent for cognitive dysfunction | |
TR201821157T4 (en) | ORAL APPLICATION SOLID COMPOSITION CONTAINING IBANDRONIC ACID OR A PHARMACEUTICALLY ACCEPTABLE SALT AND VITAMIN D. | |
EP3500291A4 (en) | Formulations for oral administration of active agents | |
WO2014137797A3 (en) | Stable glucokinase activator compositions | |
ES2666322T3 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
EP3373909A4 (en) | Vitamin k-enriched lipid emulsion formulations for the treatment of pharma toxicity | |
AR100028A1 (en) | NUTRITIONAL COMPOSITIONS CONTAINING ESTEARIDÓNIC ACID | |
PL3541783T3 (en) | Precursor compounds for providing retinoids of the vitamin a5 pathway and uses thereof | |
NZ741553A (en) | Dibenzo azepine compounds and their use in the treatment of otic diseases and disorders | |
PH12015502727A1 (en) | Methods and compositions for enhancing cognitive performance | |
AU2012386215A8 (en) | Pharmaceutical composition of milk fat globules (MFGs) zinc free | |
EP3270883A4 (en) | Scalable vitamin composition unit dosage for the treatment of fat-soluble vitamin deficiencies | |
GB201209344D0 (en) | Omega-6 enriched pufa phospholipids | |
EP3027180A4 (en) | Compositions and methods of the treatment of fatty acid metabolism disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |